Table 3.
Overview of characteristics in naïve and previously eradicated patients.
| Categories | Total | Treatment Status | p Value | |
|---|---|---|---|---|
| Naïve | Previously Treated | |||
| n, (%) | n | n | ||
| Fluoroquinolone (FLQ) resistance | 52 (47.3%) | 7 | 45 | 0.008 * |
| Clarithromycin (CLA) resistance | 57 (52.8%) | 7 | 50 | 0.002 * |
| Dual Resistance (FLQ-R and CLA-R) | 33 (30%) | 4 | 29 | 0.054 |
| Mutations | ||||
| 23S mutation | 56 (50.9%) | 7 | 49 | 0.002 * |
| gyr 91 mutation | 21 (19.1%) | 3 | 18 | 0.268 |
| gyrA mutation | 42 (38.2%) | 5 | 37 | 0.013 * |
| gyr 87 mutation | 16 (14.5%) | 3 | 13 | 0.757 |
| Histopathological scores | ||||
| Atrophy score | 0.018 * | |||
| 0 | 44 | 18 | 26 | |
| 1 | 57 | 8 | 49 | |
| 2 | 7 | 2 | 5 | |
| 3 | 1 | 0 | 1 | |
| Cellularity score | 0.018 * | |||
| 0 | 1 | 1 | 0 | |
| 1 | 39 | 15 | 24 | |
| 2 | 65 | 12 | 53 | |
| 3 | 4 | 0 | 4 | |
| Inflammatory activity | 0.002 * | |||
| 0 | 8 | 5 | 3 | |
| 1 | 56 | 17 | 39 | |
| 2 | 44 | 6 | 38 | |
| 3 | 1 | 0 | 1 | |
*p < 0.05 significance level.